Piper Sandler assumed coverage of Black Diamond Therapeutics (BDTX) with an Overweight rating and $9 price target Black Diamond is advancing lead asset silevertinib, a “potentially best-in-class” fourth generation EGFR inhibitor for treatment of non-small cell lung cancer and glioblastoma, the analyst tells investors. The less than $100M enterprise value reflected in shares ahead of multiple clinically de-risking and value creating catalysts over the next 12 months “offers an attractive entry point,” the analyst contends.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Black Diamond Therapeutics files $500M mixed securities shelf
- Promising Clinical Developments and Strong Financials Justify Buy Rating for Black Diamond Therapeutics
- Black Diamond Therapeutics Reports Positive Financial Turnaround
- Black Diamond Therapeutics reports Q3 EPS (15c), consensus (23c)
- Black Diamond Therapeutics sees cash runway into 4Q27